Information Collection

Submission of Controlled Correspondence

IC 262988 under ICR 202411-0910-010 · OMB 0910-0727.

Documents and Forms

Documents and forms in this information collection
Document Name	Document Type
0727 Competitive Generic Therapies Final guidance OCT 2022.pdf	Other-Agency Guidance
0727 Competitive Generic Therapies Final guidance OCT 2022.pdf	Other-Agency Guidance
0727 Cover Letter Attachments for Controlled Correspondence and ANDA Submissions JUNE 2023.pdf	Other-Agency Guidance
0727 Cover Letter Attachments for Controlled Correspondence and ANDA Submissions JUNE 2023.pdf	Other-Agency Guidance
0727 - CPAs draft guidance SEPT 2022.pdf	Other-Agency Guidance
0727 - CPAs draft guidance SEPT 2022.pdf	Other-Agency Guidance
0727 Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA - OCT 2022.pdf	Other-Agency Guidance
0727 Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA - OCT 2022.pdf	Other-Agency Guidance
0727 Controlled Correspondence draft DEC 2022.pdf	Other-Agency Guidance
0727 Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA.pdf	Other-Agency Guidance
0727 Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA.pdf	Other-Agency Guidance
Controlled Correspondence Related to Generic Drug Development.pdf www.fda.gov/regulatory-information/search-fda-guidance-documents/controlled-correspondence-related-generic-drug-developm	Other-Agency Guidance

IC Title:

Agency IC Tracking Number:

Is this a Common Form? No

IC Status: Modified

Obligation to Respond: Required to Obtain or Retain Benefits

CFR Citation: 21 CFR 10.115; Good guidance practice 21 CFR 314.445; Guidance documents

Information Collection Instruments:

table that charts list of instruments
Document Type	URL	Available Electronically?	Can Be Submitted Electronically?	Electronic Capability
Other-Agency Guidance		Yes	Yes	Fillable Fileable
Other-Agency Guidance		Yes	Yes	Fillable Fileable
Other-Agency Guidance		Yes	Yes	Fillable Fileable
Other-Agency Guidance		Yes	Yes	Fillable Fileable
Other-Agency Guidance		Yes	Yes	Fillable Fileable
Other-Agency Guidance	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/controlled-correspondence-related-generic-drug-development	Yes	Yes	Fillable Fileable

Line of Business: Health

Subfunction: Consumer Health and Safety

Privacy Act System of Records

Title:

FR Citation:

Number of Respondents: 500

Number of Respondents for Small Entity: 0

Affected Public: Private Sector

Private Sector: Businesses or other for-profits

Percentage of Respondents Reporting Electronically: 0 %

table that charts list of burden
	Approved	Previously Approved
Annual Number of Responses for this IC	5,000	5,000
Annual IC Time Burden (Hours)	25,000	25,000
Annual IC Cost Burden (Dollars)	0	0

Documents for IC

table that charts IC Documents
Title	Document	Date Uploaded
No associated records found

Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.

Something went wrong when downloading this file. If you have any questions, please send an email to [email protected].